Teva Seeks To Simplify With Canadian Inhalers
Launches Innovative Inhalation Device With ‘Price Advantage’
Executive Summary
Teva’s innovative asthma device, Aermony RespiClick (fluticasone propionate inhalation powder), will be accessible to over 3.8 million affected asthmatic patients in Canada in three dose options.